Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6682969 | 0.80 | KIF11 (0.42) | CYP2D6CYP3A4ALDH1A1CYP2C19TAAR1 | |
| SCHEMBL28312162 | 0.78 | CYP2D6 (0.44) | CYP2D6CYP3A4ALDH1A1CYP2C19TAAR1 | |
| SCHEMBL28500872 | 0.78 | CYP2D6 (0.41) | CYP2D6CYP3A4ALDH1A1CYP2C19TAAR1 | |
| SCHEMBL15821748 | 0.78 | CYP2D6 (0.41) | CYP2D6CYP3A4ALDH1A1CYP2C19TAAR1 | |
| SCHEMBL336626 | 0.77 | CYP2D6 (0.40) | CYP2D6CYP3A4ALDH1A1CYP2C19TAAR1 | |
| SCHEMBL6546209 | 0.77 | SIGMAR1 (0.48) | CYP2D6TAAR1MAPK1TRPA1 | |
| Hydrogen Peroxide SCHEMBL9456643 | 0.75 | ALDH1A1 (0.42) | CYP2D6CYP3A4ALDH1A1CYP2C19TAAR1 | |
| SCHEMBL4354021 | 0.75 | MAPK1 (0.42) | CYP2D6CYP3A4ALDH1A1CYP2C19TAAR1 | |
| SCHEMBL9279074 | 0.74 | MAPK1 (0.46) | CYP2D6CYP3A4ALDH1A1CYP2C19TAAR1 | |
| SCHEMBL575235 | 0.74 | MAPK1 (0.46) | CYP2D6CYP3A4ALDH1A1CYP2C19TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131660-A1 | SYNTHESIS OF 3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPIONALDEHYDE AND cis-4--2,6-DIMETHYL-MORPHOLINE (AMOROLFINE) | GALDERMA S.A. (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-2007742-A1 | PROCESS FOR PRODUCING 3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPIONALDEHYDE AND CIS-4-{3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPYL}-2,6-DIMETHYL-MORPHOLINE (AMOROLFINE) | Galderma S.A. (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007113218-A1 | PROCESS FOR PRODUCING 3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPIONALDEHYDE AND CIS-4-{3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPYL}-2,6-DIMETHYL-MORPHOLINE (AMOROLFINE) | GALDERMA S.A. (CH) | 2007-10-11 | — | — | WO | disclosed |
| EP-1842848-A1 | Process for producing 3-[4-(1,1-dimethyl-propyl)-phenyl]2-methyl-propionaldehyde and cis-4{3-[4-(1,1-dimethyl-propyl)-phenyl]2-methyl-propyl}-2,6-dimethyl-morpholine (amorolfine) | Galderma S.A. (CH) | 2007-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131660-A1 | SYNTHESIS OF 3-[4-(1,1-DIMETHYL-PROPYL)-PHENYL]-2-METHYL-PROPIONALDEHYDE AND cis-4--2,6-DIMETHYL-MORPHOLINE (AMOROLFINE) | PDK2, EML4, DEK | CYP2D6 169/4885CYP3A4 336/4885ALDH1A1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.